Awards and Recognitions
We Recognize Outstanding Achievements in our Myeloma Community
Marion State Memorial Myeloma Canada Nursing Award
In 2012, Myeloma Canada created the Marion State Memorial Myeloma Canada Nursing Award to recognize excellence in myeloma nursing care. The award was created in recognition of Marion State’s extraordinary contributions to the Canadian myeloma community. A nursing graduate from Toronto General Hospital and Ryerson University, Marion was diagnosed with multiple myeloma in 1996. Two years later, she founded the Toronto & District Multiple Myeloma Support Group, the first myeloma patient support group in Canada. The Toronto & District Multiple Myeloma Support Group provided valuable support to other patients across the country. Marion lived an active life for 15 years until her passing in 2012. The award recipient is honoured with a plaque.
Past winners have been:
- 2014: Nanette Cox (CrossCancer Institute, Edmonton)
- 2015: Marcia Culham (Tom Baker Cancer Centre, Calgary)
- 2016: Tiziana Vadacchino (Jewish General Hospital, Montreal)
- 2017: Cathy Foster (Joseph Brant Hospital (JBH) Cancer Clinic, Burlington)
Cathy Foster is a Primary Care Nurse in Hematology at the Joseph Brant Hospital (JBH) Cancer Clinic in Burlington, Ontario, and has dedicated 25 years caring for hematology/oncology patients, mentoring nurses, coordinating with the pharmacy team and most importantly, assisting oncologists and hematologists. She is the only primary hematology nurse employed at the JBH Cancer Clinic. Often described by her colleagues as doing the work of two nurses, Cathy is also known for paying great attention to patient blood test results and doesn’t hesitate to question what she sees as a critical concern. Going above and beyond to advocate for patients for treatment access, her patients feel her cheerful and uplifting spirit with an outwardly colourful disposition while remaining very professional during busy clinic times. Cathy accepted the award on December 2nd, at the Halton-Peel Area Myeloma Support Group holiday social.
Carolyn Henry Memorial TEAM Award
The Excellence in Advocacy Medal (TEAM) Award was created in 2009 to recognize outstanding achievements by patient advocates and their supporters who led successful campaigns to fight for equitable access to myeloma treatments. In 2012, the award was renamed the Carolyn Henry Memorial TEAM Award in recognition of Carolyn’s pioneering advocacy efforts. Carolyn lost her 11-year battle with myeloma in January 2012.
Past winners have been:
- 2009: Carolyn Henry, Cindy Leder and the Ontario advocacy team
- 2010: Marguerite Leask and the Manitoba advocacy team
- 2011: Carol Coleman and the New Brunswick advocacy team
- 2012: Carol Westberg
- 2013: Ev McDowell, Jeff Parton and the London & District Multiple Myeloma Support Group
- 2014: Canadian Association for Rare Disorders (CORD)
- 2015: Aldo Del Col
- 2016: Robin Sully and the Ontario Advocacy Committee
This 2016 award was presented to the Ontario Advocacy Committee, represented by Robin Sully, Jan Wleugle and the late Kirk Boyd for their outstanding efforts in helping to improve the lives of patients in Ontario.
Myeloma Canada / Cancer Research Society Operating Grant
Myeloma Canada, in partnership with the Cancer Research Society, established an annual research grant aimed at supporting the most promising Canadian myeloma research through a national competition. A scientific committee, comprised of peers, selects the best proposed project for funding.
Myeloma Canada, in partnership with the Cancer Research Society, is pleased to announce that Dr. Hong Chang, Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre and Affiliate Scientist, Toronto General Hospital Research Institute (TGHRI), is the recipient of the fourth jointly-funded Myeloma Canada/Cancer Research Society Operating Grant for his project entitled "Role of MARCKS in multiple myeloma drug resistance". The 2016 jointly funded grant was for $120,000 over two years focusing solely on myeloma research.
By analyzing protein from drug-sensitive and drug-resistant myeloma cells, Dr. Chang and his team have discovered a novel protein called pMARCKS (phosphorylated myristoylated alanine-rich C-kinase substrate) that is highly expressed in drug-resistant myeloma cells. They propose to investigate the molecular mechanisms of pMARCKS and validate pMARCKS as an important therapeutic target. To reach their goal they will establish a model to target pMARCKS with specific peptide inhibitors to overcome myeloma drug resistance. Their study will provide a potential novel therapeutic strategy to improve the outcomes of patients with the disease.
Congratulations to Dr. Chang and his team to moving us one step closer to finding a cure!